**The Open Biotechnology Journal**
*DOI: 10.2174/0118740707407791260409045456, 2026, 20, e18740707407791*
**ISSN: 1874-0707**
*1*

**SUPPLEMENTARY MATERIAL** **OPEN ACCESS**

# Translating Resveratrol Research: A Systematic Review on Patents and Clinical Trials (2000–2025)

Monika Kaurav[1,*], Roma Ghai[2,*], Niraj Pal[2] and Kandasamy Nagarajan[3]

[1]*Delhi Pharmaceutical Sciences and Research University (A State University of GNCT of Delhi), Pushp Vihar Sector-III, New Delhi-110 017, India*
[2]*Department of Pharmacology, KIET Group of Institutions (KIET School of Pharmacy), Ghaziabad, Uttar Pradesh, 201206, India*
[3]*Department of Pharmaceutical Chemistry, KIET Group of Institutions (KIET School of Pharmacy), Ghaziabad, Uttar Pradesh, 201206, India*

© 2026 The Author(s). Published by Bentham Open.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Address correspondence to these authors at the Delhi Pharmaceutical Sciences and Research University (A State University of GNCT of Delhi), Pushp Vihar Sector-III, New Delhi-110 017, India and Department of Pharmacology, KIET Group of Institutions (KIET School of Pharmacy), Ghaziabad, Uttar Pradesh, 201206, India;
E-mails: monika11kaurav@gmail.com and romaghai30@gmail.com

*Cite as:* Kaurav M, Ghai R, Pal N, Nagarajan K. Translating Resveratrol Research: A Systematic Review on Patents and Clinical Trials (2000–2025). Open Biotechnol J, 2026; 20: e18740707407791.
http://dx.doi.org/10.2174/0118740707407791260409045456

Published: April 17, 2026

***Send Orders for Reprints to reprints@benthamscience.net***

## PRISMA 2020 CHECKLIST

| Section and Topic | Item # | Checklist Item | Location where Item is Reported |
|---|---|---|---|
| **TITLE** | | | |
| Title | 1 | Identify the report as a systematic review. | Title page, abstract, introduction |
| **ABSTRACT** | | | |
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist. | Abstract section |
| **INTRODUCTION** | | | |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | Introduction |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | End of introduction |
| **METHODS** | | | |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | Methods: Literature Search |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | Methods: Literature Search |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | Methods section – keywords mentioned |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | PRISMA Figure + Methods |

| Section and Topic | Item # | Checklist Item | Location where Item is Reported |
|---|---|---|---|
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | Methods section |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (*e.g.* for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | Clinical Trial Tables and Analysis |
| | 10b | List and define all other variables for which data were sought (*e.g.* participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | Study Characteristics and Tables |
| Study risk of bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | Not explicitly reported |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (*e.g.* risk ratio, mean difference) used in the synthesis or presentation of results. | Clinical trial tables (summary stats) |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (*e.g.* tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | Qualitative synthesis described |
| | 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. | Qualitative narrative format |
| | 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | Figures 1–5, Tables 1–3 |
| | 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | Narrative + Graphs |
| | 13e | Describe any methods used to explore possible causes of heterogeneity among study results (*e.g.* subgroup analysis, meta-regression). | Not applicable (qualitative review) |
| | 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | Not reported |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | Not discussed |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | Not explicitly stated |
| **RESULTS** | | | |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | Figure 1 (PRISMA Diagram) |
| | 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | Not listed individually |
| Study characteristics | 17 | Cite each included study and present its characteristics. | Tables 1–3 |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study. | Not assessed individually |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (*e.g.* confidence/credible interval), ideally using structured tables or plots. | Tables 2 & 3 (Clinical Trials) |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | Results and Discussion |
| | 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (*e.g.* confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | Not applicable |
| | 20c | Present results of all investigations of possible causes of heterogeneity among study results. | Not explored |
| | 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | Not conducted |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | Not discussed |

| Section and Topic | Item # | Checklist Item | Location where Item is Reported |
|---|---|---|---|
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | Not formally addressed |
| **DISCUSSION** | | | |
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | Discussion section |
| | 23b | Discuss any limitations of the evidence included in the review. | Limitations under Discussion |
| | 23c | Discuss any limitations of the review processes used. | Not discussed explicitly |
| | 23d | Discuss implications of the results for practice, policy, and future research. | Conclusion section |
| **OTHER INFORMATION** | | | |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | Not registered |
| | 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | Not available |
| | 24c | Describe and explain any amendments to information provided at registration or in the protocol. | Not applicable |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | Acknowledgement or not specified |
| Competing interests | 26 | Declare any competing interests of review authors. | Not declared |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | Not mentioned |

*From:* Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, *et al*. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
For more information, visit: http://www.prisma-statement.org/